Superworth

Phathom Pharmaceuticals PHAT

Drug Manufacturers - General, Healthcare
$5.92
+3.05%
Market cap
$480.8M
PE
n/m
a loss over the last year
Forward PE
n/m
not a meaningful number
Price to sales
1.7×
EV/EBIT
n/m
a loss over the last year
Revenue, 12 months
$274.9M
+87% on a year ago
Net margin
−30.2%
Free cash flow yield
−4.4%

Phathom Pharmaceuticals trades at 1.7× sales. Its trailing earnings are negative, so it has no PE. Revenue was $274.9M over the last twelve months, up 87% on a year earlier with a −30% net margin.

Charts

Financials

Income statement for PHAT, by quarter
Income statementQ4 FY23Q1 FY24Q2 FY24Q3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26
$682K$1.9M$7.3M$16.4M$29.7M+4250%$28.5M+1392%$39.5M+439%$49.5M+203%$57.6M+94%$58.3M+104%$74.3M+88%$84.7M+71%
Cost of revenue$167K$426K$1.4M$2.4M$3.8M+2184%$3.7M+774%$5M+266%$6.2M+163%$7.6M+101%$12M+222%$15.1M+200%$18.4M+197%
Gross profit$515K$1.5M$5.9M$14M$25.8M+4919%$24.8M+1569%$34.5M+479%$43.3M+210%$49.9M+93%$46.3M+87%$59.2M+72%$66.4M+53%
R&D$13.4M−16%$9.4M−18%$7.4M−42%$8.7M−29%$8.6M−36%$9.2M−3%$9.1M+23%$7M−19%$7.5M−13%$7.8M−15%$7.8M−14%$8.7M+24%
SG&A$57M+86%$62M+233%$75.9M+301%$76.1M+225%$76.7M+35%$94.5M+52%$85.3M+12%$51.6M−32%$48.4M−37%$54M−43%$55.3M−35%$57.7M+12%
−$69.9M+50%−$70M+133%−$77.3M+144%−$70.8M+99%−$59.4M−15%−$78.9M+13%−$59.9M−23%−$15.3M−78%−$5.9M−90%−$15.5M−80%−$4M−93%−$85K−99%
Interest expense$13M+36%$17.2M+86%$17.8M+85%$18.5M+83%$18.6M+43%$18.1M+5%$17.5M−1%$16.1M−13%$16.4M−12%$15.8M−13%$15.1M−14%$15.4M−5%
Net income−$79.6M+45%−$82.9M+119%−$91.4M+123%−$85.6M+98%−$74.5M−6%−$94.3M+14%−$75.8M−17%−$30M−65%−$21.1M−72%−$30.4M−68%−$17.6M−77%−$13.9M−54%
−$1.39+5%−$1.42+60%−$1.56+86%−$1.32+74%−$1.05−25%−$1.31−8%−$1.05−33%−$0.41−69%−$0.29−72%−$0.37−72%−$0.21−80%−$0.16−61%
57.3M+39%58.4M+38%58.6M+21%64.6M+14%71M+24%72M+23%72.5M+24%73.4M+14%73.8M+4%82.1M+14%83.7M+16%84.9M+16%

EPS, diluted: 5 periods, Q4 FY21 to Q4 FY25: quarter's net income to common over its shares, to the cent.

Diluted shares: 5 periods, Q4 FY21 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.

From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.

Peers

Companies in Drug Manufacturers - General nearest Phathom Pharmaceuticals' size, closest first.

CompanyMarket capPEIts 10y median PEFwd PEP/SRevenue growthNet margin
PHATPhathom Pharmaceuticals$480.8Mn/mn/a1.7×+87%−30.2%
ARVNArvinas$491.7M47.0×50.5×1.6×−15%2.9%
PBYIPuma Biotechnology$525.5M19.6×12.3×2.3×−3%11.6%
CRMDCorMedix$420.1M2.5×4.0×0.9×+281%40.5%
IRWDIronwood Pharmaceuticals$571.7M4.5×14.8×1.5×+26%33.4%
ZVRAZevra Therapeutics$599.8M10.9×12.2×4.4×+119%42.8%
COLLCollegium Pharmaceutical$770.9M19.1×19.1×1.0×+14%5.9%
ABUSArbutus Biopharma$791.4M5.1×5.6×4.4×n/m84.2%
NATRNatures Sunshine Products$211.5M11.9×20.2×0.4×+7%3.7%
AMPHAmphastar Pharmaceuticals$1.1B15.9×20.5×1.6×+1%10.8%
OMEROmeros$1.3B11.7×11.7×n/mn/mn/m
Peer median$585.8M11.8×13.5×1.6×+11%11.6%

More on Phathom Pharmaceuticals

Each number over time

Its groups

About

Industry
Drug Manufacturers - General
Sector
Healthcare

Valuation data, not investment advice. Prices as of .